Head of Medical Affairs

Remix launched with a vision to transform patients’ lives through modulation of RNA processing. Our breakthrough science enables the identification of small molecules that influence the expression of disease‑driving mRNAs and proteins. We focus on diseases of high unmet medical need and are committed to operating with scientific rigor and urgency. With a proprietary in‑house technology platform, we have rapidly generated multiple discovery programs advancing toward the clinic. Remix Therapeutics was recognized as one of BioSpace’s Best Places to Work in Boston 2025 and is backed by leading life sciences investors. Position Summary: Remix is seeking a Head of Medical Affairs to provide medical affairs leadership for REM-422 and contribute to the development of future programs across the portfolio. REM-422 is an innovative investigational therapy targeting RNA splicing machinery, with adenoid cystic carcinoma (ACC), a rare salivary gland cancer, as its first clinical indication. With no approved therapy for ACC, this is an opportunity to help shape the medical and treatment landscape for patients with a rare cancer while playing a key role in advancing a novel therapeutic approach. Reporting directly to the Chief Medical Officer and based at our Watertown, MA headquarters, this individual will play a central role in disease education, scientific leadership, external engagement, evidence generation and trial execution, and interpretation of emerging clinical data. This is the first medical affairs hire at Remix. You will define what the function is, hire the people who follow you, and grow the organization as REM-422 moves toward approval and launch. You will also be the external scientific voice of the company, personally engaged in the field with KOLs and advocacy leaders. The role is global in scope; however, the United States is the initial focus and the first launch market. Key Responsibilities: Disease Education and Market Definition Lead development and execution of Medical Strategy with a focus on REM-422 for use in ACC. Build scientific awareness of ACC as a MYB driven disease across medical oncology, head and neck, and ENT communities, and establish Remix as a credible scientific voice in the field. Work with other key stakeholders to map the ACC patient journey: where patients present, who they see, how they are referred, and where they fall out of the system. Advance understanding of MYB biomarker testing so eligible patients can be identified, partnering with Clinical Development, Regulatory, and diagnostic partners. Generate and codify real world insight on current management patterns and unmet need and feed it into development and launch planning. Scientific Leadership and External Engagement Personally engage leading ACC, head and neck, and hematology investigators, and build the KOL network. Oversee advisory boards, congress strategy, and scientific exchange that shape how ACC is defined and treated. Build durable partnerships with ACC advocacy organizations and bring the patient's voice into development and launch decisions. Represent Remix externally in scientific and business development settings. Evidence Generation and Communication Own publication strategy and execution across ACC and AML/HR-MDS. Direct the HEOR, natural history, burden of disease, and real-world evidence to work that a disease with no approved therapy leaves undone. Run the investigator sponsored trial program and provide medical insight into company sponsored trial design, endpoints, and lifecycle strategy. Launch Readiness and Cross-Functional Partnership Partner with Clinical Development, Regulatory, and Commercial on launch preparation, contributing to the medical and scientific perspective. Ensure the clinical evidence base is accurately understood across the organization so that planning rests on what the data actually supports. <span data-contrast="aut